Date | Price Target | Rating | Analyst |
---|---|---|---|
7/29/2024 | $101.00 | Buy → Hold | Deutsche Bank |
7/1/2024 | Outperform → Mkt Perform | William Blair | |
6/7/2023 | $97.00 | Buy → Hold | Truist |
4/21/2023 | $87.00 | Neutral | Cantor Fitzgerald |
3/13/2023 | $93.00 | Equal Weight | Barclays |
10/27/2022 | Outperform → Mkt Perform | Raymond James | |
8/2/2022 | $145.00 → $95.00 | Neutral → Sell | UBS |
6/29/2022 | $128.00 | Hold | Stifel |
8-K - AMEDISYS INC (0000896262) (Filer)
10-Q - AMEDISYS INC (0000896262) (Filer)
8-K - AMEDISYS INC (0000896262) (Filer)
SC 13G/A - AMEDISYS INC (0000896262) (Subject)
SC 13G/A - AMEDISYS INC (0000896262) (Subject)
SC 13G/A - AMEDISYS INC (0000896262) (Subject)
BATON ROUGE, La., Sept. 25, 2024 (GLOBE NEWSWIRE) -- Amedisys, Inc. (NASDAQ:AMED), a leading provider of home health, hospice and high-acuity care in the home, has 92 home health and hospice care centers recognized by Strategic Healthcare Programs (SHP) for achieving the highest overall HHCAHPS patient satisfaction or CAHPS Hospice caregiver satisfaction scores of all eligible SHP clients in 2023. This includes 14 care centers awarded Premier Performer, ranking in the top 5%, and 78 care centers awarded Superior Performer, ranking in the top 20%. Thirteen care centers achieved an award in each of the last 5 years of the SHPBest program. "Nothing we do is possible without our incredible ca
NASHVILLE, Tenn., Aug. 21, 2024 (GLOBE NEWSWIRE) -- Today, Contessa Health, a subsidiary of Amedisys Inc. (NASDAQ:AMED), announced they have been selected by the Centers for Medicare & Medicaid Services (CMS) to participate in a new Medicare alternative payment model designed to support people living with dementia and their caregivers. Under CMS' Guiding an Improved Dementia Experience (GUIDE) Model, Contessa will be one of almost 400 participants building Dementia Care Programs (DCPs) across the country, working to increase care coordination and improve access to services and supports, including respite care, for people living with dementia and their caregivers. "CMS is excited to
BATON ROUGE, La., July 24, 2024 (GLOBE NEWSWIRE) -- Amedisys, Inc. (NASDAQ:AMED) today reported its financial results for the three and six-month periods ended June 30, 2024. Three-Month Periods Ended June 30, 2024 and 2023 Net service revenue increased $38.2 million to $591.2 million compared to $553.0 million in 2023.Net income attributable to Amedisys, Inc. of $32.3 million, which is inclusive of merger-related expenses totaling $11.9 million ($11.5 million, net of tax) compared to net loss attributable to Amedisys, Inc. of $80.3 million, which is inclusive of merger-related expenses totaling $125.5 million ($125.5 million, net of tax) in 2023.Net income attributa
BATON ROUGE, La., July 24, 2024 (GLOBE NEWSWIRE) -- Amedisys, Inc. (NASDAQ:AMED) today reported its financial results for the three and six-month periods ended June 30, 2024. Three-Month Periods Ended June 30, 2024 and 2023 Net service revenue increased $38.2 million to $591.2 million compared to $553.0 million in 2023.Net income attributable to Amedisys, Inc. of $32.3 million, which is inclusive of merger-related expenses totaling $11.9 million ($11.5 million, net of tax) compared to net loss attributable to Amedisys, Inc. of $80.3 million, which is inclusive of merger-related expenses totaling $125.5 million ($125.5 million, net of tax) in 2023.Net income attributa
BATON ROUGE, La., April 24, 2024 (GLOBE NEWSWIRE) -- Amedisys, Inc. (NASDAQ:AMED) today reported its financial results for the three-month period ended March 31, 2024. Three-Month Periods Ended March 31, 2024 and 2023 Net service revenue increased $15.0 million to $571.4 million compared to $556.4 million in 2023. Prior year included $15.0 million of net service revenue from our personal care business which was divested on March 31, 2023.Net income attributable to Amedisys, Inc. of $14.4 million, which is inclusive of merger-related expenses totaling $20.7 million ($19.8 million, net of tax), compared to $25.2 million in 2023.Net income attributable to Amedisys, Inc. per diluted share o
BATON ROUGE, La., Feb. 21, 2024 (GLOBE NEWSWIRE) -- Amedisys, Inc. (NASDAQ:AMED) today reported its financial results for the three-month period and year ended December 31, 2023. Three-Month Periods Ended December 31, 2023 and 2022 Net service revenue increased $8.8 million to $570.8 million compared to $562.0 million in 2022. Prior year included $15.9 million of net service revenue from our personal care business which was divested on March 31, 2023.Net income attributable to Amedisys, Inc. of $19.3 million, which is inclusive of $11.5 million in costs associated with with our merger transactions, compared to $31.7 million in 2022.Net income attributable to Amedisys, Inc. per diluted s